You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華森製藥(002907.SZ):收到奧利司他膠囊的藥品再註冊批準通知書
格隆匯 02-17 18:43

格隆匯2月17日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局覈準簽發的關於公司產品奧利司他膠囊的《藥品再註冊批準通知書》。奧利司他膠囊是我國目前唯一獲批的用於肥胖或體重超重(體重指數≥24kg/m2)患者的口服治療藥物,其主要通過減少食物中脂肪吸收來降低體重。該產品是《基於臨牀的肥胖症多學科診療共識(2021年版)》《2011年中國成人肥胖專家共識》《中國成人血脂異常防治指南》等指南/專家共識推薦用藥。據米內網數據顯示,該產品2023年在中國網上藥店終端的銷售額達16億元,同比增長101.64%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account